Development And Evaluation of Proliposome Powder for Enhanced Delivery of Deflazacort

This research thesis investigates the development and evaluation of Proliposome powder as a novel drug delivery system for enhancing the delivery of Deflazacort, a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. Deflazacort is used in the management of various inflammatory and autoimmune conditions, including rheumatoid arthritis, asthma, and inflammatory bowel disease. However, its clinical utility is limited by poor aqueous solubility, low bioavailability, and systemic side effects. The formulation development phase involves the preparation of Proliposome by solvent evaporation technique, various lipid excipients and surfactants are screened to optimize the encapsulation efficiency, stability, and release characteristics of the Proliposome formulation. Total six batches were formulated from that batch 4 was giving the maximum results so selected as optimized batch. The evaluation of the formulated proliposome powder encompasses a comprehensive assessment of its physicochemical properties, including particle size, morphology, drug loading, and encapsulation efficiency. The entrapment efficiency was found in the range of 84.64 ± 0.5 to 91.01 ± 06. In vitro dissolution studies are conducted to investigate the release profile of Deflazacort from the proliposome powder, simulating physiological conditions encountered upon administration. The results were found in the range of 83.48% to 93.60%. The research findings contribute to the development of a novel drug delivery platform for Deflazacort, offering improved solubility, bioavailability, and therapeutic efficacy. The developed formulation has the potential to enhance patient compliance and therapeutic outcomes in the treatment of inflammatory and autoimmune disorders requiring glucocorticoid therapy.